Metronidazolo Baxter S.P.A. (Metronidazole)

Metronidazole enters susceptible microorganisms and is reduced by their anaerobic metabolic pathways, producing reactive nitro radicals. These radicals bind to DNA and other critical macromolecules, disrupting nucleic acid synthesis and leading to cell death, while human cells are largely unaffected because they lack the necessary reduction environment.

The dosing regimen for Metronidazolo Baxter S.P.A. is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals should follow local guidelines and adjust the dose as needed for individual patients.

Safety data for metronidazole during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives and risk assessment with their healthcare provider.

To order Metronidazolo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metronidazolo contains metronidazole, a well‑established nitroimidazole with broad activity against anaerobic bacteria and certain protozoa. Compared with alternatives such as tinidazole or ornidazole, metronidazole has a longer history of clinical use, extensive safety data, and is generally less expensive, though individual drug choice depends on pathogen susceptibility and patient tolerance.

Metronidazolo should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Ensure the vial is kept upright, avoid freezing, and discard any solution that appears discolored or contains particles before administration.

Metronidazolo is given by intravenous infusion under the supervision of a qualified healthcare professional. The solution is diluted in an appropriate compatible IV fluid and infused over the recommended period, typically ranging from 30 minutes to several hours, depending on the clinical protocol.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions (including anaphylaxis), Stevens‑Johnson syndrome, hepatic dysfunction, and neutropenia. Patients should be monitored for neurological symptoms, skin changes, liver function abnormalities, and signs of infection or bleeding, and any concerning findings should prompt immediate medical evaluation.

Metronidazolo is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is advised for individuals with severe hepatic impairment, those receiving disulfiram, and patients with a history of severe neurological disorders. Clinicians should evaluate each patient’s medical history before prescribing.